Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Lifestyle Health and Longevity

AI Scribes Save Clinicians 13–16 Minutes a Day — and Boost Visit Volume by 1.7%, Study Finds

by Team Lumida
April 13, 2026
in Health and Longevity
Reading Time: 3 mins read
A A
0
AI Investment Boom: How Tech Giants Are Leading the Charge

"Machine Learning & Artificial Intelligence" by mikemacmarketing is licensed under CC BY 2.0

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp
  • AI scribe adoption was associated with 13 fewer minutes per day in the EHR and 16 fewer minutes on documentation — a 3% and 10% reduction respectively — according to a JAMA study covering more than 8,500 clinicians across five academic medical centers
  • Primary care providers saw the biggest gains: 25 fewer minutes in the EHR and nearly 27 fewer minutes on clinical notes daily; clinicians who used scribes in 50%+ of visits saved 21 fewer EHR minutes and 27 fewer documentation minutes
  • AI scribe adoption was linked to 0.5 additional patient visits per week and $167/month in additional evaluation and management revenue per clinician — described by researchers as a “conservative lower bound” of financial benefit that health systems can compare against implementation costs
  • The tools did not reduce after-hours EHR work, suggesting clinicians are using reclaimed time for other tasks like responding to patient messages or reviewing AI-generated notes for accuracy — a finding that limits the burnout-reduction case for scribes

What Happened?

A major new study published in JAMA provides the most rigorous large-scale evidence to date on how AI scribes affect clinical workflows. Conducted across five academic medical centers with more than 8,500 clinicians, the research found that adopting an AI scribe — which records provider-patient conversations and generates draft clinical notes — was associated with 13 fewer minutes per day in the electronic health record and 16 fewer minutes on documentation. The tools also increased weekly visit volume by 0.5 appointments per clinician, translating to $167 in additional monthly revenue. Primary care providers, female clinicians, advanced practice providers, and those who used scribes most frequently saw the largest time savings — with some primary care physicians reclaiming nearly 27 minutes daily from documentation alone.

Why It Matters?

Administrative burden — particularly time spent on EHR documentation — has become one of the leading drivers of clinician burnout, a crisis that has worsened physician shortages and contributed to rising healthcare costs. AI scribes from companies including Microsoft (Nuance), Oracle, Epic, Amazon, and Abridge have been adopted rapidly by health systems on the promise of reducing that burden, but rigorous evidence on their actual impact has been scarce. This JAMA study fills a critical gap. The 10% reduction in documentation time and 1.7% increase in visit volume suggest meaningful, if modest, productivity gains — and the $167/month revenue bump, while small, gives health systems a starting point for calculating ROI against implementation costs. The finding that after-hours EHR work did not decline complicates the burnout narrative, however, suggesting clinicians may be absorbing time savings into other administrative tasks rather than logging off earlier.

What’s Next?

The AI scribe market is expanding rapidly, with major health IT vendors racing to embed ambient documentation into existing EHR workflows. The JAMA study’s subgroup findings — that higher-frequency users and primary care clinicians benefit most — suggest that health system ROI on scribe deployment will depend heavily on implementation depth and specialty mix. Researchers note that the $167/month revenue figure is a conservative floor estimate; full financial modeling would need to account for reduced overtime, lower turnover, and patient throughput gains. Future research will need to address whether time savings compound over time as clinicians become more fluent with AI-generated notes, and whether the absence of after-hours relief eventually closes as note quality improves and review time falls.

Source: Healthcare Dive

Previous Post

Iran Still Has Thousands of Missiles — and Intelligence Says It Can Get More Out of the Ground

Next Post

Oil Could Hit $140–$150 If the Hormuz Blockade Holds, Veteran Trader Warns — and $103 Is Just the Beginning

Recommended For You

America’s Fertility Rate Just Hit a Record Low — and the Numbers Are Getting Harder to Ignore

by Team Lumida
3 days ago
America’s Fertility Rate Just Hit a Record Low — and the Numbers Are Getting Harder to Ignore

The U.S. general fertility rate fell to 53.1 births per 1,000 women in 2025 — a record low — while the total fertility rate dropped to 1.57, well...

Read more

Healthcare Roundup: Medicare Advantage Gets a $13B Boost, Drug Tariffs Hit 100%, and Wegovy Goes Discount

by Team Lumida
4 days ago
person sitting while using laptop computer and green stethoscope near

A packed week in healthcare: Medicare Advantage rates came in at a better-than-expected 2.48% increase, Trump unveiled 100% tariffs on some brand-name drugs, Gilead and Neurocrine spent $8B...

Read more

Why Americans Pay More for Healthcare Than Anyone Else in the World

by Team Lumida
6 days ago
doctor holding red stethoscope

A new WSJ analysis breaks down the structural forces behind America's sky-high healthcare costs — from monopoly hospitals and unregulated drug prices to administrative bloat and physician salaries...

Read more

Genetic Tests Come Under Federal Scrutiny as Trump Administration Targets Lab Fraud

by Team Lumida
7 days ago
Supreme Court Signals It Will Strike Down Trump’s Birthright Citizenship Order

The CMS has opened a public comment period on how to curb fraudulent genetic testing billing — a billion-dollar problem involving unnecessary tests marketed directly to consumers and...

Read more

94% of Physicians Have Adopted or Want AI — But Accuracy Concerns Remain the Top Barrier

by Team Lumida
2 weeks ago
a man holding a ball in his right hand

A Doximity survey of more than 3,000 physicians finds that AI adoption in clinical practice has surged from 47% to 63% in under a year — but more...

Read more

Up to 10 Million Americans Could Lose Medicaid by 2028 Under New Work Requirements

by Team Lumida
2 weeks ago

A new Urban Institute and Robert Wood Johnson Foundation analysis finds that 5 to 10 million people could be disenrolled from Medicaid in 2028 due to work requirements...

Read more

One-Third of Americans Now Use AI for Health Advice — and Many Are Skipping the Doctor

by Team Lumida
2 weeks ago
One-Third of Americans Now Use AI for Health Advice — and Many Are Skipping the Doctor

A KFF poll of 1,300+ U.S. adults finds roughly 1 in 3 now use AI for health information — as often as social media — with 40%+ uploading...

Read more

The Weight Loss Drug Race: What’s Available Now and What’s Coming Next

by Team Lumida
2 weeks ago
The Weight Loss Drug Race: What’s Available Now and What’s Coming Next

The obesity drug market is set for a major expansion, with Eli Lilly's once-daily pill targeting April FDA approval, Novo Nordisk launching a high-dose shot, and six additional...

Read more

GLP-1s Aren’t a Shortcut. They’re a Powerful Tool That Still Needs a Real Health Strategy

by Team Lumida
3 weeks ago
GLP-1s Aren’t a Shortcut. They’re a Powerful Tool That Still Needs a Real Health Strategy

Key Takeaways Powered by lumidawealth.com GLP-1 drugs can be highly effective for weight management, but they work best when combined with diet, physical activity, and clinical follow-up. The bigger...

Read more

Sleep Regularity Is the Underrated Health Lever Most People Miss

by Team Lumida
3 weeks ago
woman sleeping on bed under blankets

Key Takeaways Powered by lumidawealth.com A consistent sleep and wake time may be one of the simplest high-impact health habits. Healthy sleep is not just about hours. Regular timing...

Read more
Next Post
Geopolitical Forces Shape Oil Market Dynamics

Oil Could Hit $140–$150 If the Hormuz Blockade Holds, Veteran Trader Warns — and $103 Is Just the Beginning

Bitcoin Could Drop to $50K Before a Potential Fed-Driven Rally

The Bitcoin Leverage Stack Just Got a New Layer: Stablecoins Backed by Strategy's Preferred Shares

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

China’s Financial Overhaul: Xi’s Strategy to Rebalance $9.1 Trillion Debt Crisis

China’s Central Bank Focuses on Enhancing Domestic Consumption

August 3, 2024
Four AI-Era Roles That Could Become Real Businesses

Four AI-Era Roles That Could Become Real Businesses

December 15, 2025
logo

Oracle Raises Revenue Outlook as AI Infrastructure Demand Surges

March 11, 2026

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips AI demand Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC Semiconductor stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018